Did Pfizer Doctor Its Numbers?Joseph Weber
William C. Steere Jr. is in a strange bind. As chief executive of Pfizer Inc., one of the nation's healthiest drug companies, he should want to flaunt his company's double-digit earnings prospects. And yet, as chairman of the drug industry's main Washington lobbying group, the Pharmaceutical Manufacturers Assn. (PMA), Steere has to convince skeptical legislators that drugmaker profits already are under pressure. President Clinton's health-care reform, he argues, could endanger the industry's future.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Tesla Unveils ‘World’s Fastest Production Car’ and Electric Big Rig
- Norway Idea to Exit Oil Stocks Is ‘Shot Heard Around the World’
- Getting a Dog May Save Your Life, Especially If You’re Single
- The Questionable Math Behind Manafort’s Extravagant Home Renovations
- Musk Dusts Off the Fundraising Playbook With Semi, Roadster Orders